EU-Funded Research on Influenza

Octavi Quintana
Director - Health
DG Research
European Commission
EU Research: From basic to applied, from animal to human

- 15 research projects funded since year 2000 under FP5 and FP6
- Focus on new vaccines, antivirals, surveillance and animal health
- Involvement of Industry and Academia
- New call for proposals dedicated to Flu Research: **deadline 22 March 2006**
- Over 40 million Euro investment in Influenza Research (**including 20 M dedicated call**)
- **New sector:** Emerging Infectious Diseases (**in humans**). More relevance in FP7
**2006, Key year for EU Influenza Research:**

- Early start, some promising results already available
- Critical mass of ongoing collaborative research projects
- New call for proposals

**Animal Flu**
- MUCADJ 1 M€
- ESNIP 0.27 M€
- FLUPAN 2.1 M€
- AVIFLU 1.8 M€
- NOVAFLU 1.7 M€

**Human Flu**
- VIRGIL 9 M€
- HEALTHY POULTRY 1.2 M€
- LAB-ON-SITE 1.5 M€
- VIZIER 13 M€
- SARS/FLU VACCINE 1.6 M€
- Universal Vaccine 1.2 M€
- FLUVACC 9.2 M€
- FLUAID 1.2 M€
- EPIZONE 14 M€
A big, collaborative EU effort with wide international dimension

More than 120 partner laboratories, companies and institutions, from 32 countries:

- 16 EU Member States
- Australia, Bulgaria, Canada, China, Gabon, Hong-Kong, Indonesia, Norway, Pakistan, Russia, South Africa, Switzerland, Thailand, Turkey, USA, Vietnam
- Many public-private partnerships (SMEs, pharma)
- More than 300 scientists

UNIVERSITIES, PUBLIC RESEARCH CENTERS AND INSTITUTIONS IN EU FLU PROJECTS:
- Human influenza
- Animal influenza

PRIVATE COMPANIES:
- Human influenza
- Animal influenza
The Influenza Research Portfolio: Human Flu Projects

VACCINES: Faster, more effective, better targeted

- **MUCADJ**: Mucosal adjuvants for intranasal influenza immunization
- **FLUPAN**: Preparing for an Influenza Pandemic
- **NOVAFLU**: Novel Vaccination Strategies and Vaccine Formulations for Epidemic and Pandemic Influenza Control
- **SARS/FLU VACCINE**: Development of a Combined Influenza/SARS Vaccine
- **FLUVACC**: Live Attenuated Replication-Defective Influenza Vaccine
- **UNIVERSAL VACCINE**: Universal Vaccine
ANTIVIRALS: Discovery and Monitoring Resistance

• **VIRGIL**: European Vigilance Network for the Management of Antiviral Drug Resistance

• **VIZIER**: Comparative Structural Genomics of Viral Enzymes Involved in Replication
A Dedicated Call for Proposals: SSP-5B INFLUENZA

SCIENTIFIC SUPPORT TO POLICIES: SPECIAL CALL ON AVIAN / PANDEMIC INFLUENZA
www.cordis.lu/lifescihealth/ssp.htm

- Published on 22nd December 2005
- Deadline: 22 March 2006
- 20 Million Euro
- For Research, Coordination and Support projects (STREP, CA and SSA)
- 11 Tasks to be covered by projects on animal and human influenza
- Private/public partnerships, multidisciplinary research
- Involvement of affected countries is encouraged
A Dedicated Call for Proposals: SSP-5B INFLUENZA

Providing health and security to the people of Europe (HUMAN FLU RESEARCH) 10M€

**HOW DOES THE VIRUS OPERATE?**
- Defining molecular markers of pathogenicity in highly pathogenic influenza (STREP)

**KEEPING TRACK OF ITS SPREAD**
- Strengthening of the research support to surveillance of influenza (STREP)

**MAKING MORE VACCINE DOSES**
- Clinical research on the immunogenicity of pandemic influenza vaccines (STREP)

**COORDINATING EFFORTS**
- European Coordination Conference/Workshop on influenza research (SSA)
Conclusions

- This may be the first time in history that we can prepare for a global pandemic in advance.

- Europe's research effort is providing a good foundation on which to mount our defences.

- Public support to research on emerging infectious diseases such as influenza will continue in the future.